Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
Janet Pope Janetbirdope
3 years 10 months ago
Do you see #JAKis causing weight gain? 429 Pts BUT during #COVID19 - 68% gained wt in RA 1.5 Kg mean; and more in SpA 71% w 2.6 Kg. Was it Rx or COVID related? #ACR22 abst0291 @RheumNow
Richard Conway RichardPAConway
3 years 10 months ago
Ruiz et al. bDMARD/tsDMARD use in RA after breast cancer. Low use, 15.5% on bDMARD, 1.5% on tsDMARD. Stable use over last 10 years @rheumnow #ACR22 Abstr#0080 https://t.co/0L6uuVtQQw https://t.co/xBH1bUdeSD
Bella Mehta bella_mehta
3 years 10 months ago
#disparities study using admin data
- 580 pts with incidence childhood #SLE with LN
- LN codes before SLE codes - more likely publicly insured, rural area, Hispanic ethnicity, kidney transplant
- differential access!!
@RADoctor @rheumnow #ACR22 abst#0068 https://t.co/uryCZq94dX
Dr. Rachel Tate uptoTate
3 years 10 months ago
Early Izokibep (IL17Ai) data demonstrated clinically meaningful, dose-dependent improvement across PROs, particularly sleep, pain, function ,+ SF36 and PsAID subdomains in PsA pts. Pts w/ baseline enthesitis had greater benefit. Abs 0199 #ACR22 @RheumNow https://t.co/sXVdwGPVnd https://t.co/Cxyfp6OXOY
TheDaoIndex KDAO2011
3 years 10 months ago
Did you get the updated #COVIDbooster before you arrived at #ACR22? Answers are anonymous @rheumnow
Robert B Chao, MD doctorRBC
3 years 10 months ago
Use of AI to detect sacroilitis in axSpA and nr-axSpA.
Pre-trained AI neural network can detect sacroilitis, especially new data, similar to human radiology experts.
Abs#0383 @RheumNow #ACR22 https://t.co/5hdrKxT3HP
Patricia Harkins DrTrishHarkins
3 years 10 months ago
‼️Frailty in Vasculitis‼️
👉VascStrong using VPPRN
✏️ FRAIL scale
👉 n=328
🌟21.6% frail
🌟42.1% pre frail
💥 frailty assoc ⬆️ pain, fatigue and ⬇️ mood and fn
💥⬆️ wt and females higher frailty
Abst0444
#ACR22 #GeriRheum @RheumNow @SattuiSEMD
Janet Pope Janetbirdope
3 years 10 months ago
Elderly onset #rheumatoid #arthritis does worse than younger people. Data from Japan - Benefit is less and side effects more. Less remission and worse HAQ scores. ?due to RA differences or changes due to age or both or neither? #ACR22 abst0244 @RheumNow @ACRheum https://t.co/FqvLA765Cu
Richard Conway RichardPAConway
3 years 10 months ago
Remuzgo-Martinez et al. Serum endothelin-1 in CTD-ILD. Significantly higher levels than healthy controls. No difference between CTD-ILD and IPF. @rheumnow #ACR22 Abstr#0123 https://t.co/Jf3AumSnjt https://t.co/Xki8LEEcnV
Richard Conway RichardPAConway
3 years 10 months ago
de Boysson et al. Beta-blockers may prevent aortic dilation in LVV GCA (0% vs 23%). 65 patients, retrospective , and patients were on beta-blockers for other reasons, but thought-provoking @rheumnow #ACR22 Abstr#0477 https://t.co/AVmIwCk3LV https://t.co/Plv5tcN5mR
Richard Conway RichardPAConway
3 years 10 months ago
Auroux et al report differential micro-RNA signatures in hand OA compared to controls (15 upregulated, 4 downregulated). No difference erosive vs non-erosive hand OA. May elucidate pathophys but also ?treatment target @rheumnow #ACR22 Abstr#0023 https://t.co/Kzv8WDmHRU https://t.co/4nCuTjvR6d
Richard Conway RichardPAConway
3 years 10 months ago
Gisslander et al Cluster analysis in AAV in Sweden. 5 groups. 2 PR3+ groups, younger, ENT or nerve involvement - good prognosis. 2 older MPO+ groups - lung or renal involvement - worse prognosis. @rheumnow #ACR22 Abstr#0433 https://t.co/itokBTOujS https://t.co/PG6CpZvN1a
Olga Petryna DrPetryna
3 years 10 months ago
#abst0129 #acr22 @rheumnow analysis 6 Euro studies of active RA, PsA, axSpA &secondary failure of TNFαi showed golimumab to be effective 2nd-line Rx. GLM show improvement in Dis activity, QoL& high retention( 2/3 pts on Rx after 12mo). https://t.co/6OeKwJpqQp
Richard Conway RichardPAConway
3 years 10 months ago
Kirby et al @colmkirby22 . Subclinical GCA in newly diagnosed PMR. 25 patients. 20% had LVV on US - TA in all, axillary in 1. All 5 developed clinical GCA over 1 year. @rheumnow #ACR22 Abstr#0478 https://t.co/xMMjH2XCUD https://t.co/JEtwEGTEbP
